pentobarbital will minimize the extent or influence of terbinafine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.
pentobarbital will decrease the level or effect of glecaprevir/pibrentasvir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will lessen the level or influence of pimavanserin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of. Prevent coadministration if possible. Keep track of for minimized pimavanserin efficacy. An increase in pimavanserin dosage may be necessary.
pentobarbital will reduce the level or impact of suvorexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor. Robust CYP3A4 inducers might lessen suvorexant efficacy; if greater suvorexant dose required, usually do not exceed twenty mg/day
pentobarbital will decrease the extent or effect of etravirine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
pentobarbital increases toxicity of ifosfamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. CYP3A4 inducers may perhaps enhance the metabolism of ifosfamide to its Lively alkylating metabolites.
In keeping with AAN suggestions on convulsive position epilepticus, EEG monitoring is necessary when administering pentobarbital.[2] Clinicians will have to bear in mind that pentobarbital is commonly baffled with phenobarbital, another drug with differing dosages and the same mechanism of motion.
pentobarbital will lower the extent or impact of fentanyl by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep track of Carefully. Coadministration of fentanyl with CYP3A4 inducers could lead on to a minimize in fentanyl plasma concentrations, deficiency of efficacy or, possibly, advancement of the withdrawal syndrome inside a client who has produced Actual physical dependence to fentanyl.
pentobarbital will minimize the level or impact of larotrectinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital decreases outcomes of hemin by pharmacodynamic antagonism. Use Warning/Check. Drugs that maximize delta-aminolevulinic acid synthetase may possibly decrease hemin result.
pentobarbital will lower the extent or effect of lopinavir by affecting check here hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital will lower the extent or outcome of alosetron by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unfamiliar.
pentobarbital will decrease the extent or result of isavuconazonium sulfate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
Contraindicated (one)pentobarbital will reduce the extent or outcome of lumefantrine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with solid CYP3A4 inducers can lead to decreased serum concentrations and loss of antimalarial efficacy